Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.

Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D'Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, Gatell JM; BEST Study Team..

AIDS. 2003 Apr 11;17(6):831-40.

PMID:
12660530
2.

Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.

van Rossum AM, Dieleman JP, Fraaij PL, Cransberg K, Hartwig NG, Burger DM, Gyssens IC, de Groot R.

Pediatrics. 2002 Aug;110(2 Pt 1):e19.

PMID:
12165618
3.

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.

Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ.

Antimicrob Agents Chemother. 2001 Oct;45(10):2710-5.

4.

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.

Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R.

J Infect Dis. 2001 Apr 1;183(7):1116-20.

PMID:
11237839
5.

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Burger DM, van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, Scherpbier HJ, Hoetelmans RM, Vulto AG, de Groot R; Dutch Study Group for Children with HIV-1 Infection..

Antimicrob Agents Chemother. 2001 Mar;45(3):701-5.

6.

Dose-finding study of a once-daily indinavir/ritonavir regimen.

Hugen PW, Burger DM, ter Hofstede HJ, Koopmans PP, Stek M, Hekster YA, Reiss P, Lange JM.

J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):236-45.

PMID:
11115954
7.

Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection.

van Rossum AM, de Groot R, Hartwig NG, Weemaes CM, Head S, Burger DM.

AIDS. 2000 Sep 29;14(14):2209-10. No abstract available.

PMID:
11061667
8.

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.

Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD.

Ann Intern Med. 2000 Jul 4;133(1):35-9.

PMID:
10877738
9.

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.

Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV.

Clin Infect Dis. 2000 Jun;30 Suppl 2:S151-9. Review.

PMID:
10860900
10.

Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections.

van Rossum AM, Niesters HG, Geelen SP, Scherpbier HJ, Hartwig NG, Weemaes CM, Veerman AJ, Suur MH, de Graeff-Meeder ER, Slieker WA, Hop WC, Osterhaus AD, Burger DM, De Groot R.

J Pediatr. 2000 Jun;136(6):780-8.

PMID:
10839877
11.

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW.

Antimicrob Agents Chemother. 2000 Apr;44(4):1029-34.

12.

Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.

Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W, Hekster YA.

Antivir Ther. 1998;3(4):215-20.

PMID:
10682141
13.

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.

Gatti G, Vigano' A, Sala N, Vella S, Bassetti M, Bassetti D, Principi N.

Antimicrob Agents Chemother. 2000 Mar;44(3):752-5.

14.

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.

Viganò A, Dally L, Bricalli D, Sala N, Pirillo M, Saresella M, Trabattoni D, Vella S, Clerici M, Principi N.

J Pediatr. 1999 Dec;135(6):675-82.

PMID:
10586168
15.

Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.

Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA.

J Chromatogr B Biomed Sci Appl. 1999 Apr 30;727(1-2):139-49.

PMID:
10360433
16.

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E.

Antimicrob Agents Chemother. 1998 Nov;42(11):2784-91.

17.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD.

JAMA. 1998 Jul 1;280(1):35-41.

PMID:
9660361
18.

Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.

Wintergerst U, Hoffmann F, Sölder B, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH.

Pediatr Infect Dis J. 1998 Jun;17(6):495-9.

PMID:
9655541
19.

A phase I/II study of the protease inhibitor indinavir in children with HIV infection.

Mueller BU, Sleasman J, Nelson RP Jr, Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P, Mistry G, Winchell G, Zwerski S, Sei S, Wood LV, Zeichner S, Pizzo PA.

Pediatrics. 1998 Jul;102(1 Pt 1):101-9.

PMID:
9651421
20.

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.

Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, Calles NR, Kirkpatrick SB, Simon C.

J Pediatr. 1998 Mar;132(3 Pt 1):543-6.

PMID:
9544920
Items per page

Supplemental Content

Support Center